We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Docetaxel in Patients with Anthracycline-Resistant Advanced Breast Cancer.
- Authors
Vici, Patrizia; Belli, Franca; Di Lauro, Luigi; Amodio, Antonella; Conti, Francesca; Foggi, Paolo; Gionfra, Tommaso; Morelli, Maria Francesca; Botti, Claudio; Ferraironi, Alessandro; Lopez, Massimo
- Abstract
Objective: To better determine docetaxel activity in patients with well-defined anthracycline-resistant breast cancer. Methods: From October 1996, we carried out a phase II trial in 69 heavily pretreated patients with advanced breast cancer with docetaxel 100 mg/m[sup 2] by a 1-hour infusion on day 1, with cycles repeated every 3 weeks. Patients were classified as having primary anthracycline resistance (n = 32), secondary anthracycline resistance (n = 7), anthracycline pretreatment (n = 22) or no anthracycline pretreatment (n = 8). Results: Among 68 evaluable patients, we observed 6 (9%) complete responses and 27 (40%) partial responses, for an overall response rate of 49% (95% confidence interval 37–61%); the disease remained stable in 17 patients (25%). Responses according to the above subgroups were as follows: primary anthracycline resistance 41%, secondary anthracycline resistance 43%, anthracycline pretreatment 64% and no anthracycline pretreatment 43%. The median time to response, median time to progression and median overall survival were 2, 7 and 10 months, respectively. Myelosuppression was the dose-limiting toxicity, with grade 4 neutropenia occurring in 47% of the patients and neutropenic fever in 12%. G-CSF was added in the case of grade 4 febrile neutropenia; a 25% reduction in the dose of docetaxel was required in 4 patients. Other side effects were mild. Conclusions: The results of the present trial confirm the high activity of docetaxel in heavily pretreated patients with advanced breast cancer, including those with strictly defined anthracycline resistance.Copyright © 2001 S. Karger AG, Basel
- Subjects
DOCETAXEL; ANTHRACYCLINES; BREAST cancer; ANTINEOPLASTIC agents; POLYCYCLIC compounds; ANTINEOPLASTIC antibiotics
- Publication
Oncology, 2001, Vol 60, Issue 1, p60
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000055298